Hot Features
Premium
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Period:
Draw Mode:
| Volume | 0 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Diffusion Pharmaceuticals Inc | DFFN | NASDAQ | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 4.40 | 19:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 4.40 | 4.40 |
| Trades | Shares Traded | Average Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0 | - | 4.14 - 7.785 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| - | 0 | US$ 4.40 | USD |
Diffusion Pharmaceuticals Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 24.97M | 5.68M | - | 7.15M | -2.17M | -0.38 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Diffusion Pharmaceuticals News
| Date | Time | Source | News Article |
|---|---|---|---|
| 4/23/2024 | 07:00 | Edgar (US Regulatory) | Form 8-K - Current report |
| 4/11/2024 | 18:55 | Edgar (US Regulatory) | Form SC 13G - Statement of acquisition of beneficial.. |
| 4/05/2024 | 15:06 | Edgar (US Regulatory) | Form 8-K - Current report |
| 4/04/2024 | 06:00 | Edgar (US Regulatory) | Form 8-K - Current report |
| 3/29/2024 | 15:02 | Edgar (US Regulatory) | Form 10-K - Annual report [Section 13 and 15(d), not S-K.. |
| 3/28/2024 | 07:36 | Edgar (US Regulatory) | Form 8-K - Current report |
| 3/18/2024 | 15:32 | Edgar (US Regulatory) | Form 8-K - Current report |
| 3/06/2024 | 15:05 | Edgar (US Regulatory) | Form SC 13G/A - Statement of acquisition of beneficial.. |
| 3/05/2024 | 07:51 | Edgar (US Regulatory) | Form 8-K - Current report |
| 2/28/2024 | 16:02 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of.. |
| 2/14/2024 | 08:23 | Edgar (US Regulatory) | Form SC 13G/A - Statement of acquisition of beneficial.. |
| 2/09/2024 | 16:02 | Edgar (US Regulatory) | Form SC 13D - General statement of acquisition of beneficial.. |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical DFFN Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 1 Month | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 3 Months | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 6 Months | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 1 Year | 5.64 | 7.785 | 4.14 | 5.75 | 13,666 | -1.24 | -21.99% |
| 3 Years | 1.0833 | 14.025 | 0.249 | 0.950581 | 580,195 | 3.32 | 306.17% |
| 5 Years | 5.01 | 14.025 | 0.249 | 1.36 | 1,845,719 | -0.61 | -12.18% |
Diffusion Pharmaceuticals Description
| Diffusion Pharmaceuticals Inc is a clinical-stage biotechnology company. It is focused on extending the life expectancy of cancer patients by improving the effectiveness of current standard-of-care treatments, including radiation therapy and chemotherapy. The company's lead product candidate is trans sodium crocetinate (TSC), which is used for the treatment of glioblastoma multiforme (GBM) and metastatic brain cancer. |
